CD274 and small cell lung carcinoma: Clinical trials such as CASPIAN, IMpower133, ASTRUM‐005, and CAPSTONE have demonstrated that anti‐PD‐L1 blockades (atezolizumab, durvalumab, and adebrelimab) and the anti‐PD‐1 blockade serplulimab significantly prolong overall survival (OS), establishing them as the standard first‐line treatment for ES‐SCLC [9, 10, 11, 12].